Sangamo Therapeutics(US:SGMO)2025-11-06 13:05Financial Performance - Sangamo Therapeutics reported a consolidated net loss of $34.9 million, or $0.11 per share, for Q3 2025, compared to a net income of $10.7 million, or $0.04 per share, in Q3 2024[9]. - Revenues for Q3 2025 were $0.6 million, a decrease of $48.8 million from $49.4 million in Q3 2024, primarily due to the collaboration agreement with Genentech recorded in the previous year[11]. - Total operating expenses on a GAAP basis for Q3 2025 were $36.1 million, down from $38.8 million in Q3 2024, driven by lower personnel costs and licensing expenses[12][13]. - Revenues for Q3 2025 were $581 thousand, a significant decrease from $49,412 thousand in Q3 2024[26]. - Total operating expenses for Q3 2025 were $36,134 thousand, compared to $38,781 thousand in Q3 2024, reflecting a reduction in costs[26]. - Research and development expenses for the nine months ended September 30, 2025, were $81,232 thousand, down from $87,846 thousand in the same period of 2024[26]. - The net loss for Q3 2025 was $34,930 thousand, compared to a net income of $10,672 thousand in Q3 2024[26]. - The company reported a loss from operations of $35,553 thousand in Q3 2025, compared to an income of $10,631 thousand in Q3 2024[26]. Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $29.6 million, down from $41.9 million as of December 31, 2024[14]. - Cash and cash equivalents as of September 30, 2025, were $29,616 thousand, a decrease from $41,918 thousand at the end of 2024[27]. - Total assets decreased to $88,643 thousand as of September 30, 2025, from $101,635 thousand at the end of 2024[27]. - Total stockholders' equity fell to $6,243 thousand as of September 30, 2025, down from $22,770 thousand at the end of 2024[27]. Future Outlook - The company expects total operating expenses in 2025 to be in the range of approximately $135 million to $155 million on a GAAP basis[15]. - Non-GAAP total operating expenses for 2025 are projected to be approximately $125 million to $145 million, excluding estimated non-cash stock-based compensation and depreciation[16]. - Sangamo's financial guidance for 2025 remains contingent on securing adequate additional funding[22]. Research and Development - Sangamo is preparing for a potential Biologics License Agreement (BLA) submission for isaralgagene civaparvovec as early as Q1 2026[10]. - The Phase 1/2 STAND study for chronic neuropathic pain has commenced patient enrollment, with the first patient expected to be dosed in the coming months[10]. - The mean annualized eGFR slope observed in the STAAR study for Fabry disease was 1.965 mL/min/1.73m²/year at 52 weeks across 32 patients[6]. - Sangamo is exploring collaborations and partnerships to advance its Fabry disease program and other initiatives[21]. Other Income - Sangamo received $6 million from Pfizer for the exercise of a buyout option related to a 2008 license agreement[6].